IQVIA’s Breakthrough Natural Language Processing Platform Receives 2019 Fierce Innovation Award

“We are honored to receive this award, which acknowledges our commitment to developing technologies that use AI/ML to improve health,” said Ben Hughes, senior vice president, Artificial Intelligence & Real World Data at IQVIA. “Our teams are leveraging natural language processing, artificial intelligence and machine learning to drive healthcare breakthroughs from early discovery to clinical research, through commercialization and beyond.”

The IQVIA Linguamatics NLP platform uniquely combines flexibility, scale and data transformation to analyze petabytes of unstructured data. The NLP platform supports the entire spectrum of life science and healthcare applications – ranging from gene mapping and target identification to health economics and outcomes research, market intelligence activities, and patient care and outcomes. The NLP text-mining is part of IQVIA’s artificial intelligence and machine learning software portfolio, helping clients seeking to speed up drug development and improve patient outcomes by breaking down data silos, boosting innovation, and generating new actionable insights.

The Fierce Innovation Awards highlight companies that demonstrate innovative solutions, technologies and services that have the potential to make the greatest impact for biotech and pharma companies. Winners and finalists’ applications were reviewed by an exclusive panel of executives from major biotech and pharma companies. All applications were evaluated based on effectiveness, technical innovation, competitive advantage, financial impact and true innovation.

Winners were announced in the 2019 Innovation Report published by FierceHealthcare in December 2019.

For more information on IQVIA AI and ML solutions, please visit https://www.iqvia.com/solutions/innovative-models/artificial-intelligence-and-machine-learning.

About Questex

At Questex, we are passionate about driving business outcomes. We connect buyers and sellers and help both achieve their goals. We are online, on devices and live with experiential engagements. We understand the buyer’s behavior and evolving needs and connect them with the seller through continual touchpoints. From discovery through purchase and purchase through advocacy, we supply unmatched access, insight, engagement and turnkey solutions all in one place.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 65,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Click here to subscribe to Mobile Alerts for IQVIA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200130005428/en/